Oxford BioDynamics (OBD) and King’s College London (KCL) have partnered to use OBD’s EpiSwitch technology to identify patients at risk of rheumatoid arthritis (RA) who can benefit from abatacept treatment.

Related Keywords

United Kingdom , Alexandre Akoulitchev , , Professor Andy , Oxford Biodynamics , Andrew Cope , Professor Cope , Bio Developments , Pipelines , Emerging Markets , Rheumatoid Arthritis , Clinical Trial , Clinical Research , Clinical Trials ,